HIMS Q3 2025 Earnings Call Cheat Sheet and Analysis Guide

Based on the extensive historical Q2 earnings data I've gathered, I'll create a comprehensive cheat sheet for HIMS Q3 2025 earnings. HIMS Q3 2025 EARNINGS CHEAT SHEET

Category	What to Look For	Historical Context (Q3 2024)	Key Numbers to Watch
REVENUE	• Total revenue growth YoY • Online Revenue vs. Wholesale Revenue split • Sequential growth Q2→Q3 • Full-year guidance raise	• Q3 2024: $401.6M (↑77% YoY) • Online: $392.6M, Wholesale: $9.0M • Q2→Q3 growth: +27%	• Target: ~$520-550M range • YoY growth: Look for 25-35% • Sequential: 15-20% typical
PROFITABILITY	• Gross margin % • Operating margin trajectory • Net income vs. net loss • Adjusted EBITDA & margin	• Q3 2024: 79% gross margin • Net income: $75.6M (tax benefit) • Adj EBITDA: $51.1M (13% margin)	• Gross margin: 77-80% range • Watch for GAAP profitability continuation • Adj EBITDA margin: 11-13%
SUBSCRIBERS	• Total subscribers (end of period) • YoY subscriber growth % • Subscriber adds QoQ • Exclude vs. include GLP-1 metrics	• Q3 2024: 2.047M (↑44% YoY) • Excluding GLP-1: 40% growth mentioned	• Target: 2.5-2.7M subscribers • Watch for 20%+ YoY growth • QoQ adds: 200K-400K
KEY METRICS	• Monthly Online Revenue per Avg Subscriber • Average Order Value (AOV) • Net Orders	• Monthly Rev/Sub: $67 • AOV: $147 • Net Orders: 2,664K	• Monthly Rev/Sub: $70-75 • AOV: $150-160 • Net Orders: 2.8-3.0M
GUIDANCE	• Q4 2025 revenue guidance • Full-year 2025 guidance update • Adjusted EBITDA outlook	• Q4 2024 guidance: $465-470M rev • FY 2024: $1.460-1.465B raised to $1.476B actual • FY Adj EBITDA: $173-178M → $177M actual	• Q4 2025: $570-600M • FY 2025: Reaffirm/raise $2.3-2.4B • FY Adj EBITDA: $270-320M

SEGMENTS TO WATCH	Specific Phrases & Topics
GLP-1 / Weight Loss	• "Compounded GLP-1" mentions • Weight loss revenue contribution • Subscriber mix: GLP-1 vs. core • Branded vs. compounded availability • Regulatory commentary on 503B compounding
Personalization	• "Personalized care" or "personalized solutions" • Multi-specialty usage (customers with >1 condition) • Cross-sell metrics between categories
Specialty Growth	• Dermatology momentum • Mental health update • Hair loss growth • Sexual health trends • Primary care expansion
Margins & Efficiency	• "Operating leverage" • "Marketing efficiency" or CAC trends • "Fulfillment optimization" • "Gross margin expansion drivers" • Technology/platform investments
Brand Strength	• Hims vs. Hers performance • Organic growth mentions • Brand awareness metrics • Mobile app adoption

FINANCIAL DETAILS	What to Listen For
Revenue Quality	• Subscription revenue % vs. one-time • Revenue retention/churn comments • Wholesale revenue trajectory • Deferred revenue balance changes
Operating Expenses	• Marketing as % of revenue (Q3 2024: 45%) • Operations & support leverage • Tech & development investment • G&A as % of revenue • Stock-based comp: $24-25M/quarter
Cash Flow	• Operating cash flow generation • Free cash flow positive/growth • CapEx for affiliated pharmacy • Cash & investments balance
Balance Sheet	• Inventory levels (medication supply) • Deferred revenue (prepayments) • No debt to monitor • Working capital position

MANAGEMENT COMMENTARY	Key Phrases to Listen For
🟢 POSITIVE SIGNALS	• "Accelerating growth" • "Market share gains" • "Operating leverage" • "Ahead of expectations" • "Expanding into new categories" • "Regulatory clarity" • "Strong unit economics"
🟡 WATCH ITEMS	• "Normalizing" • "Moderating" • "Strategic investments" • "Near-term headwinds" • "Mix shift" • "Promotional activity"
🔴 CONCERNS	• "Competitive pressure" • "Regulatory uncertainty" • "Slowing growth" • "Margin pressure" • "Customer acquisition challenges" • "Reimbursement issues"

ANALYST Q&A TOPICS	Questions to Anticipate
GLP-1 Specific	• Branded vs. compounded revenue split • What happens if FDA removes shortage status? • Pricing strategy for GLP-1 offerings • Subscriber retention for GLP-1
Competition	• Ro, Hone Health, other DTC telehealth • Traditional healthcare incumbents • Amazon/Costco entering weight loss
Path to Profitability	• When will GAAP profitability be sustained? • Margin expansion roadmap • Investment priorities vs. profit optimization
Regulatory	• State-level telehealth regulations • DEA controlled substance prescribing • FTC/FDA enforcement activity • 503B pharmacy regulatory environment

QUESTIONS TO ASK YOURSELF POST-CALL:

• ✅ Did revenue meet/beat guidance? By how much?
• ✅ Are margins expanding as expected?
• ✅ Is subscriber growth healthy excluding GLP-1?
• ✅ Did they raise full-year guidance?
• ✅ Is management confident or cautious on GLP-1 tailwinds?
• ✅ Are unit economics improving (CAC/LTV)?
• ✅ Any new category launches or partnerships announced?